Saturday, February 21, 2026
21.7 C
Bengaluru

IQVIA Sponsors Race for 7 to Commemorate World Rare Disease Day

#IQVIA Sponsors Race for 7 to commemorate World Rare Disease Day

“IQVIA is delighted to be associated for the fourth consecutive year as the main sponsor of Race for 7. While rare diseases, by virtue of their definition, affect relatively fewer number of patients, the overall number of rare disease patients is large enough to warrant more focused attention.

We hope that the public will come forward in large numbers to participate in Race for 7 and help amplify the voice of the rare disease community. Race for 7 is a unique way of engaging the community with those who matter most – patients and their caregivers for a common cause,” said Amit Mookim, Managing Director, IQVIA – South Asia.

Rare Diseases is a key therapeutic focus for IQVIA who has provided clinical services for more than 258 rare disease studies in 87 countries worldwide since 2011.

Race for 7 is held simultaneously in multiple cities and two countries – India and the USA. Over the years, the run has expanded and in 2019 it will be conducted over February and March across 13 Indian cities – Bengaluru, Mysuru, Chennai, Kolkata, Mumbai, Jaipur, Coimbatore, Bikaner, Hyderabad, New Delhi, Ahmedabad, Thiruvananthapuram, Kochi.

– MedicinMan Press Release

Hot this week

India’s Pharma Renaissance: Private Equity at the Helm

Indian pharmaceuticals have long been known as the “pharmacy...

The ₹5 Snack SKU: A Silent Indian Metabolic Crisis

Executive Summary — The Paradox of Scale In the annals...

Sleep Apnea: Apnimed Pill to Replace CPAP Machine?

In India, where urban sleep debt is rising, obesity...

Why the World Still Doesn’t Celebrate Antibiotic Breakthroughs llike Zaynich

When a new cancer drug shows promise, it trends...

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Topics

India’s Pharma Renaissance: Private Equity at the Helm

Indian pharmaceuticals have long been known as the “pharmacy...

The ₹5 Snack SKU: A Silent Indian Metabolic Crisis

Executive Summary — The Paradox of Scale In the annals...

Sleep Apnea: Apnimed Pill to Replace CPAP Machine?

In India, where urban sleep debt is rising, obesity...

From Overuse to Overreaction: Recalibrating India’s C-Section Debate

India’s caesarean section debate is drifting toward polarisation. On one...

Sanofi’s Decision not to Renew Paul Hudson as CEO Marks a Structural Shift

In big pharma, leadership changes are rarely impulsive. They...

THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL

How a niche Indian topicals manufacturer outgrew its CDMO...

Indian Pharma: Are Regulatory Gaps From Generics Following Biosimilars?

Transparency, Trust, and the Problem of “Invisible Evidence” in...
spot_img

Related Articles

spot_imgspot_img